Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1490684 | 0.85 | NPC1 (0.52) | NPC1RAB9AMAPTPOLBLMNA | |
| SCHEMBL1490217 | 0.82 | NPC1 (0.52) | NPC1RAB9AMAPTPOLBMAPK1 | |
| SCHEMBL1490651 | 0.82 | NPC1 (0.48) | NPC1RAB9AMAPTPOLBSMN1; SMN2 | |
| SCHEMBL1490425 | 0.82 | RAB9A (0.48) | NPC1RAB9AMAPTPOLBLMNA | |
| SCHEMBL1490594 | 0.82 | MGLL (0.52) | NPC1RAB9APOLBLMNASMN1; SMN2 | |
| SCHEMBL3556358 | 0.81 | MAPT (0.61) | NPC1RAB9AMAPTPOLBLMNA | |
| SCHEMBL1490720 | 0.81 | NPC1 (0.50) | NPC1RAB9AMAPTPOLBMAPK1 | |
| SCHEMBL1490620 | 0.81 | RAB9A (0.47) | NPC1RAB9AMAPTPOLBLMNA | |
| SCHEMBL1490433 | 0.80 | NPC1 (0.44) | NPC1RAB9APOLBLMNAMAPK1 | |
| SCHEMBL1490619 | 0.80 | NPC1 (0.44) | NPC1RAB9APOLBMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732452-B2 | Thiophene derivatives which are HM74A agonists | HOFFMANN-LA ROCHE INC. (US) | 2010-06-08 | — | — | US | claimed |
| EP-1931651-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-18 | — | — | EP | claimed |
| US-20070161650-A1 | Novel thiophene derivatives which are HM74A agonists | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-12 | — | — | US | claimed |
| WO-2007039482-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | claimed |
| US-20070072873-A1 | Novel thiophene derivatives which are HM74A agonists | HOFFMANN-LA ROCHE INC. | 2007-03-29 | — | — | US | claimed |
| US-7732452-B2 | Thiophene derivatives which are HM74A agonists | HOFFMANN-LA ROCHE INC. (US) | 2010-06-08 | — | — | US | disclosed |
| EP-1931651-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-18 | — | — | EP | disclosed |
| US-20070161650-A1 | Novel thiophene derivatives which are HM74A agonists | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-12 | — | — | US | disclosed |
| WO-2007039482-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072873-A1 | Novel thiophene derivatives which are HM74A agonists | HOFFMANN-LA ROCHE INC. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072873-A1 | Novel thiophene derivatives which are HM74A agonists | GPR84, GPR174, MRGPRX1 | NPC1 1082/4885RAB9A 813/4885MAPT 4815/4885 |
| US-20070161650-A1 | Novel thiophene derivatives which are HM74A agonists | GPR84, GPR174, MRGPRX1 | NPC1 1082/4885RAB9A 813/4885MAPT 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.